Professor Lin Yunfeng, Chief Scientist of Yunhai Biotech, Receives the “2025 China Industry-University-Research Collaboration Innovation Person Award

On March 15, the 17th China Industry-University-Research Collaboration Innovation Conference was held in Beijing under the theme of “Deep Integration of Technological and Industrial Innovation to Foster New Quality Productive Forces.” During the conference, the winners of the 2025 Science and Technology Innovation Awards were officially announced by the China Association for the Promotion of Industry-University-Research Collaboration. Professor Lin Yunfeng, Chief Scientist of Yunhai Biotech, was honored with the “2025 China Industry-University-Research Collaboration Innovation Person Award.”

This prestigious recognition not only highlights Professor Lin’s outstanding achievements in scientific innovation and the translation of research into real-world applications, but also reflects strong recognition of Yunhai Biotech’s commitment to independent innovation and its long-standing dedication to advancing the integration of industry, academia, and research.

Established by the China Association for the Promotion of Industry-University-Research Collaboration and approved by the National Office for Science and Technology Awards, the China Industry-University-Research Collaboration Innovation Person Award is a national-level honor and a highly respected distinction in the field of collaborative innovation. It recognizes individuals who have made outstanding contributions to promoting deeper industry-university-research integration, technological innovation, and the commercialization of scientific achievements, with broad influence across the industry and strong national recognition.

As Chief Scientist of Yunhai Biotech, Professor Lin has long focused on the research of DNA tetrahedral framework nucleic acid drug systems. With Professor Lin’s team serving as the company’s core scientific foundation, Yunhai Biotech has continued to advance patent development, technology innovation, and industrial translation centered on tetrahedral framework nucleic acids, with the goal of building a globally oriented universal technology platform for framework nucleic acids. The DNA tetrahedral framework nucleic acid drug system developed through years of dedicated research by Professor Lin and his team has become a cornerstone of Yunhai Biotech’s technology platform and industrial strategy.

In terms of translational development, tetrahedral framework nucleic acids are demonstrating broad and promising application potential. In 2025, Yunhai Biotech and Professor Lin’s team continued to achieve breakthroughs in multiple areas, including retinal macular degeneration, ALS treatment, miRNA delivery, and the delivery of active compounds derived from traditional Chinese medicine. Among these advances, the team proposed a drug delivery technology based on tetrahedral framework nucleic acid platforms, offering a promising new pathway for overcoming critical bottlenecks in small nucleic acid drug delivery. At the same time, Yunhai Biotech has continued to advance the development of framework nucleic acid therapeutics in ophthalmology and has launched the world’s first investigator-initiated clinical trial (IIT) of a framework nucleic acid drug in humans.

This award is both an honor and a responsibility. Looking ahead, Yunhai Biotech will continue to be guided by scientific and technological innovation, leveraging its core tetrahedral framework nucleic acid technology to further deepen industry-university-research collaboration, accelerate the translation of original research achievements into clinical and industrial applications, and expand the boundaries of framework nucleic acid technologies in medicine and the broader health sector.

We once again extend our warmest congratulations to Professor Lin Yunfeng on receiving the “2025 China Industry-University-Research Collaboration Innovation Person Award.” Taking this achievement as a new starting point, Yunhai Biotech will remain committed to innovation-driven development, continue to unlock the value of tetrahedral framework nucleic acid technology, and contribute further to advances in biotechnology and human health.